Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization

Overview of attention for article published in Frontiers in immunology, July 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 3 news outlets

twitter: 3 X users

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis

AP News, 30 Jul 2024

Intranasal administration of a synthetic Toll-Like Receptor 4 (TLR4) agonist INI-2004 significantly reduces allergy symptoms…

Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis

Yahoo! Finance USA, 30 Jul 2024

Intranasal administration of a synthetic Toll-Like Receptor 4 (TLR4) agonist INI-2004 significantly reduces allergy symptoms…

Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis

PR Newswire, 30 Jul 2024

News provided by Inimmune Jul 30, 2024, 09:00 ET MISSOULA, Mont., July 30, 2024 /PRNewswire/ -- Inimmune, a leading biotech…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.